E3 PreliminaryPreliminaryPEM unclearReview-NarrativePeer-reviewedMachine draft
Hypothalamus-Pituitary-Adrenal Dysfunction in Cholestatic Liver Disease.
Petrescu, Anca D, Kain, Jessica, Liere, Victoria et al. · Frontiers in endocrinology · 2018 · DOI
Quick Summary
This review examines how the stress hormone system (HPA axis) works and what happens when it breaks down in people with liver disease. The HPA axis is like your body's control center that manages stress responses and many other important functions. The authors explain how inflammation in the liver can disrupt this system, potentially leading to the fatigue and other symptoms seen in both liver disease and chronic fatigue syndrome.
Why It Matters
HPA axis dysfunction is a recognized feature in ME/CFS, and this review provides mechanistic insight into how chronic inflammation disrupts the stress hormone system—a pathway potentially relevant to ME/CFS pathology. Understanding how inflammatory states suppress HPA axis function could inform therapeutic strategies for both liver disease and post-infectious fatigue syndromes like ME/CFS.
Observed Findings
- Proinflammatory cytokines stimulate glucocorticoid release from adrenals while simultaneously inhibiting bile acid efflux from the liver
- Chronic hepatic inflammation leads to both cholestasis and impaired glucocorticoid metabolism in the liver
- Glucocorticoids interact with self-oscillating transcription factors that generate circadian rhythms in gene expression in brain and liver
- HPA axis becomes depressed as a consequence of chronic liver inflammation and impaired glucocorticoid metabolism
Inferred Conclusions
- HPA axis dysfunction is correlated with cholestatic liver disorders and is driven by inflammatory signaling pathways
- Circadian rhythm disruption through glucocorticoid-transcription factor interactions may contribute to pathophysiology in chronic liver disease
- The negative feedback loop between inflammation and hormone metabolism perpetuates both hepatic and neuroendocrine dysfunction
Remaining Questions
- How do the HPA axis dysfunctions in cholestatic liver disease compare mechanistically to those documented in ME/CFS?
- Can HPA axis restoration reverse or prevent the progression of cholestasis and associated inflammation?
- What are the optimal glucocorticoid replacement strategies that restore circadian rhythm function without worsening liver dysfunction?
What This Study Does Not Prove
This review does not directly study ME/CFS patients or prove that HPA axis dysfunction in cholestatic liver disease is identical to that in ME/CFS. It does not establish causation—the correlation between liver inflammation and HPA suppression does not prove which causes which. The findings in liver disease models may not fully translate to ME/CFS mechanisms without direct comparative studies.
Tags
Symptom:Fatigue
Biomarker:CytokinesGene ExpressionBlood Biomarker
Method Flag:Exploratory Only
Metadata
- DOI
- 10.3389/fendo.2018.00660
- PMID
- 30483216
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →